In a recent article with DCAT Value Chain Insights, our CEO, Marc Funk discussed the key trends in bio/pharmaceutical outsourcing as part of its ‘5 Minutes With’ series.
The topics Marc discussed with the publication include:
- What are the top trends impacting CDMOs this year? The main focus needs to be on preparing for the winter season to ensure we can adapt to any demand increases.
- Will the adoption by some CDMOs/CMOs to create an end-to-end service model prove to be a continuing trend? Many CDMOs claim to be fully integrated in the value chain but aren’t fully established. Furthermore, many pharma companies prefer to spread risk by working with multiple CDMOs.
- How do you see the product mix (small molecules and biologics) in the industry’s pipeline evolving? Good CDMOs should have both capabilities, but it is important not to forget that small molecules make up the largest proportion of the drug pipeline.
- How do you see drug development and bio/pharmaceutical outsourcing five years from now? Unless the US government takes action, big pharma companies will continue to outsource bio CDMO services to Asian CDMOs causing a decrease in the number of Western-based CDMOs.